MX2023001059A - Modulacion de la respuesta inmunitaria mediada por la aminopeptidasa 2 del reticulo endoplasmico (erap2). - Google Patents

Modulacion de la respuesta inmunitaria mediada por la aminopeptidasa 2 del reticulo endoplasmico (erap2).

Info

Publication number
MX2023001059A
MX2023001059A MX2023001059A MX2023001059A MX2023001059A MX 2023001059 A MX2023001059 A MX 2023001059A MX 2023001059 A MX2023001059 A MX 2023001059A MX 2023001059 A MX2023001059 A MX 2023001059A MX 2023001059 A MX2023001059 A MX 2023001059A
Authority
MX
Mexico
Prior art keywords
endoplasmic reticulum
erap2
modulation
immune response
mediated immune
Prior art date
Application number
MX2023001059A
Other languages
English (en)
Spanish (es)
Inventor
Carmelo Romano
Sahar Gelfman
Aris Baras
Giovanni Coppola
Manuel Allen Revez Ferreira
Ann Ligocki
Arden Moscati
Eli A Stahl
Jack A Kosmicki
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2023001059A publication Critical patent/MX2023001059A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8103Exopeptidase (E.C. 3.4.11-19) inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485Exopeptidases (3.4.11-3.4.19)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/11Aminopeptidases (3.4.11)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Analytical Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
MX2023001059A 2020-07-25 2021-07-23 Modulacion de la respuesta inmunitaria mediada por la aminopeptidasa 2 del reticulo endoplasmico (erap2). MX2023001059A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063056562P 2020-07-25 2020-07-25
US202163171672P 2021-04-07 2021-04-07
PCT/US2021/043062 WO2022026336A1 (en) 2020-07-25 2021-07-23 Modulation of endoplasmic reticulum aminopeptidase 2 (erap2)-mediated immune response

Publications (1)

Publication Number Publication Date
MX2023001059A true MX2023001059A (es) 2023-04-26

Family

ID=77564145

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001059A MX2023001059A (es) 2020-07-25 2021-07-23 Modulacion de la respuesta inmunitaria mediada por la aminopeptidasa 2 del reticulo endoplasmico (erap2).

Country Status (10)

Country Link
US (1) US20230059929A1 (https=)
EP (1) EP4188963A1 (https=)
JP (1) JP2023536437A (https=)
KR (1) KR20230043888A (https=)
CN (1) CN116194484A (https=)
AU (1) AU2021316196B2 (https=)
CA (1) CA3189755A1 (https=)
IL (1) IL299986A (https=)
MX (1) MX2023001059A (https=)
WO (1) WO2022026336A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4416286A1 (en) 2021-10-14 2024-08-21 Regeneron Pharmaceuticals, Inc. Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors
US12613286B2 (en) 2024-01-22 2026-04-28 Garrett Transportation I Inc. System and method for battery parameter recharacterization
CN118593462B (zh) * 2024-06-28 2026-01-27 沈阳药科大学 鼠尾草酸作为erap1的抑制剂在制备治疗强直性脊柱炎药物中的应用

Also Published As

Publication number Publication date
AU2021316196A1 (en) 2023-02-23
IL299986A (en) 2023-03-01
JP2023536437A (ja) 2023-08-25
CN116194484A (zh) 2023-05-30
EP4188963A1 (en) 2023-06-07
AU2021316196B2 (en) 2025-09-25
WO2022026336A1 (en) 2022-02-03
CA3189755A1 (en) 2022-02-03
US20230059929A1 (en) 2023-02-23
KR20230043888A (ko) 2023-03-31

Similar Documents

Publication Publication Date Title
MX2023001059A (es) Modulacion de la respuesta inmunitaria mediada por la aminopeptidasa 2 del reticulo endoplasmico (erap2).
CO2022004902A2 (es) Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer
CO2019006292A2 (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
AR116753A1 (es) Proceso de preparación de un derivado de pirazolsulfonilamida
CL2015002641A1 (es) Método para el tratamiento de la enfermedad de parkinson.
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
CL2019001415A1 (es) Composición para promover la diferenciación de y para proteger las células madre neuronales y método para inducir la regeneración neural utilizando la misma.
CL2022003511A1 (es) Inhibidores de alk2 para el tratamiento de la anemia.
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
MX2022013233A (es) Metodo de seleccion de pacientes para tratamiento con una combinacion de un inhibidor de axl y un modulador de punto de control inmunitario.
MX2018015022A (es) Métodos para el tratamiento de la enfermedad de alzheimer.
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
MX2023000763A (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
MX2021009488A (es) Uso de vibegron para tratar la vejiga hiperactiva.
MX2023011720A (es) Una composicion para su uso en el tratamiento de mhc-i-opatias.
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante
DOP2022000095A (es) Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con nmp con navitoclax
MX2023014341A (es) Tratamiento de la enfermedad cerebrovascular con agentes de la proteina 3 homologa de notch del locus neurogenico (notch3).